• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Provectus axes CEO Culpepper for expense account violations

December 30, 2016 By Sarah Faulkner

Provectus axes CEO Culpepper for expense account violationsProvectus Biopharmaceuticals Inc. (OTCQB:PVCT) said this week that its board of directors voted unanimously to terminate CEO and chief operating officer Peter Culpepper, after an internal investigation revealed that Culpepper violated the company’s expense account reimbursement policy.

The Knoxville, Tenn.-based company said it has established a search committee and is actively seeking a new CEO. In the meantime, Provectus president Timothy Scott will serve as interim CEO.

Scott has been with Provectus since 2002. He previously worked on the executive team of Photogen, serving as the company’s chief operating officer, director and interim CEO.

Provectus is investigating a number of therapies for skin cancer, liver cancer and breast cancer. PV-10, the company’s investigational oncology drug, is an ablative immunotherapy that is being studied as a treatment for solid tumor cancers. The company has finished a phase II trial evaluating PV-10 in patients with metastatic melanoma.

Provectus has also received orphan drug designation from the FDA for melanoma and hepatocellular carcinoma therapies.

The company is running clinical trials for PH-10, a topical drug, as treatment for psoriasis and atopic dermatitis, including a phase II trial of PH-10 as a topical therapy for the 2 conditions.

In August, the company raised $6 million in a public offering of 240,000 shares of Series B convertible preferred stock and warrants to purchase 24,000,000 shares of common stock at $25.00 apiece. The warrants had an exercise price of ¢0.27 per share and will expire on August 30, 2021.

Filed Under: Featured, Immunotherapy, Oncology, Wall Street Beat Tagged With: Provectus Biopharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS